MedTrace Logo

Autologous Platelet-rich Plasma as a Treatment for Macular Holes

NCT06323902 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2024-03-21

No results posted yet for this study

Summary

For a series of patients with full-thickness macular hole, an autologous plasma rich in growth factors was developed in the form of a clot and applied to the retinal defect. These patients were followed up for a period of one year, obtaining substantial improvement both anatomically and functionally.

Conditions

  • Macular Holes
  • Macular Hole of Left Eye (Disorder)
  • Macular Hole of Right Eye (Disorder)

Interventions

PROCEDURE

Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation

In the operating room through pars plana vitrectomy after having completed the complete air exchange, with the help of a Backwash Charles cannula, the PRGF membrane is placed in the macular hole and C3F8 gas is left in the posterior chamber, the first hour in the recumbent position. supine and subsequently face down during the first postoperative week.

Sponsors & Collaborators

  • Clinica Oftalmologica Paredes

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-25
Primary Completion
2023-06-08
Completion
2024-02-29

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06323902 on ClinicalTrials.gov